Santen Pharmaceutical Co., Ltd. (SNPHF)
USD 10.53
(0.0%)
USD 10.53
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 27.46 Billion JPY | 0.0% |
| 2023 | 28.19 Billion JPY | 122.43% |
| 2022 | 12.67 Billion JPY | 428.21% |
| 2021 | 2.4 Billion JPY | 22.14% |
| 2020 | 1.96 Billion JPY | -44.85% |
| 2019 | 3.56 Billion JPY | 1.8% |
| 2018 | 3.5 Billion JPY | -53.94% |
| 2017 | 7.59 Billion JPY | -41.16% |
| 2016 | 12.91 Billion JPY | -49.06% |
| 2015 | 25.35 Billion JPY | 42867.8% |
| 2014 | 59 Million JPY | -32.18% |
| 2013 | 87 Million JPY | -24.35% |
| 2012 | 115 Million JPY | -24.34% |
| 2011 | 152 Million JPY | 105.41% |
| 2010 | 74 Million JPY | 72.09% |
| 2009 | 43 Million JPY | -60.91% |
| 2008 | 110 Million JPY | -97.92% |
| 2007 | 5.27 Billion JPY | -3.08% |
| 2006 | 5.44 Billion JPY | -17.66% |
| 2005 | 6.61 Billion JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 34.69 Billion JPY | 0.0% |
| 2024 Q4 | 27.46 Billion JPY | 0.0% |
| 2024 FY | 27.46 Billion JPY | -2.61% |
| 2024 Q3 | 33.62 Billion JPY | 0.0% |
| 2024 Q2 | 33.9 Billion JPY | 0.0% |
| 2023 Q3 | 37.09 Billion JPY | -2.71% |
| 2023 Q2 | 38.12 Billion JPY | 70.95% |
| 2023 FY | 28.19 Billion JPY | 122.43% |
| 2023 Q4 | 28.19 Billion JPY | -23.98% |
| 2023 Q1 | 22.3 Billion JPY | 75.93% |
| 2022 Q3 | 21.22 Billion JPY | 6.56% |
| 2022 Q1 | 10.04 Billion JPY | 318.54% |
| 2022 Q2 | 19.91 Billion JPY | 98.26% |
| 2022 Q4 | 12.67 Billion JPY | -40.26% |
| 2022 FY | 12.67 Billion JPY | 428.21% |
| 2021 FY | 2.4 Billion JPY | 22.14% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q4 | 2.4 Billion JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 FY | 1.96 Billion JPY | -44.85% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q4 | 6.6 Billion JPY | 0.0% |
| 2019 Q2 | - JPY | 0.0% |
| 2019 Q4 | 3.56 Billion JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 FY | 3.56 Billion JPY | 1.8% |
| 2019 Q1 | - JPY | -100.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 FY | 3.5 Billion JPY | -53.94% |
| 2018 Q4 | 3.5 Billion JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 Q1 | - JPY | -100.0% |
| 2017 Q1 | - JPY | -100.0% |
| 2017 FY | 7.59 Billion JPY | -41.16% |
| 2017 Q4 | 7.61 Billion JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2016 Q2 | - JPY | 0.0% |
| 2016 Q1 | - JPY | -100.0% |
| 2016 FY | 12.91 Billion JPY | -49.06% |
| 2016 Q4 | 12.94 Billion JPY | 0.0% |
| 2016 Q3 | - JPY | 0.0% |
| 2015 Q3 | 28.32 Billion JPY | 46329.51% |
| 2015 Q4 | 25.35 Billion JPY | -10.49% |
| 2015 FY | 25.35 Billion JPY | 42867.8% |
| 2015 Q1 | 77 Million JPY | 30.51% |
| 2015 Q2 | 61 Million JPY | -20.78% |
| 2014 FY | 59 Million JPY | -32.18% |
| 2014 Q4 | 59 Million JPY | -6.35% |
| 2014 Q3 | 63 Million JPY | -11.27% |
| 2014 Q2 | 71 Million JPY | -13.41% |
| 2014 Q1 | 82 Million JPY | -5.75% |
| 2013 FY | 87 Million JPY | -24.35% |
| 2013 Q4 | 87 Million JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q1 | - JPY | -100.0% |
| 2012 Q4 | 115 Million JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2012 Q1 | - JPY | -100.0% |
| 2012 FY | 115 Million JPY | -24.34% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 FY | 152 Million JPY | 105.41% |
| 2011 Q1 | - JPY | -100.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2011 Q4 | 152 Million JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 FY | 74 Million JPY | 72.09% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q4 | 74 Million JPY | 0.0% |
| 2009 Q4 | 43 Million JPY | 0.0% |
| 2009 FY | 43 Million JPY | -60.91% |
| 2008 FY | 110 Million JPY | -97.92% |
| 2007 FY | 5.27 Billion JPY | -3.08% |
| 2006 FY | 5.44 Billion JPY | -17.66% |
| 2005 FY | 6.61 Billion JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | -22.968% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 28.075% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -25552.45% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | -37.082% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -141521.015% |